Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
Business Wire India– PHOENIXPhase 3 trial topline results on track for mid-2024 and will inform regulatory next steps in the EU – Final decision from the European Commission expected by…